Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

256 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Appetite control.
Wynne K, Stanley S, McGowan B, Bloom S. Wynne K, et al. J Endocrinol. 2005 Feb;184(2):291-318. doi: 10.1677/joe.1.05866. J Endocrinol. 2005. PMID: 15684339 Review.
Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment.
Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P. Ashby DR, et al. Among authors: wynne kj. Kidney Int. 2009 Jul;76(2):199-206. doi: 10.1038/ki.2009.114. Epub 2009 Apr 22. Kidney Int. 2009. PMID: 19387475 Clinical Trial.
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Wynne K, et al. Int J Obes (Lond). 2006 Dec;30(12):1729-36. doi: 10.1038/sj.ijo.0803344. Epub 2006 Apr 18. Int J Obes (Lond). 2006. PMID: 16619056 Clinical Trial.
Attenuated peptide YY release in obese subjects is associated with reduced satiety.
le Roux CW, Batterham RL, Aylwin SJ, Patterson M, Borg CM, Wynne KJ, Kent A, Vincent RP, Gardiner J, Ghatei MA, Bloom SR. le Roux CW, et al. Among authors: wynne kj. Endocrinology. 2006 Jan;147(1):3-8. doi: 10.1210/en.2005-0972. Epub 2005 Sep 15. Endocrinology. 2006. PMID: 16166213
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Wynne K, et al. Diabetes. 2005 Aug;54(8):2390-5. doi: 10.2337/diabetes.54.8.2390. Diabetes. 2005. PMID: 16046306 Clinical Trial.
PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR. Field BC, et al. Among authors: wynne k. Diabetes. 2010 Jul;59(7):1635-9. doi: 10.2337/db09-1859. Epub 2010 Mar 31. Diabetes. 2010. PMID: 20357366 Free PMC article. Clinical Trial.
Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism.
Cegla J, Jones B, Seyani L, Papadoulou D, Wynne K, Martin NM, Meeran K, Chapman R, Donaldson M, Goldstone AP, Tan T. Cegla J, et al. Among authors: wynne k. Clin Endocrinol (Oxf). 2013 May;78(5):738-42. doi: 10.1111/cen.12043. Clin Endocrinol (Oxf). 2013. PMID: 22998100
The mechanism of action for oxyntomodulin in the regulation of obesity.
Wynne K, Field BC, Bloom SR. Wynne K, et al. Curr Opin Investig Drugs. 2010 Oct;11(10):1151-7. Curr Opin Investig Drugs. 2010. PMID: 20872318 Review.
Can gut hormones control appetite and prevent obesity?
Chaudhri OB, Wynne K, Bloom SR. Chaudhri OB, et al. Among authors: wynne k. Diabetes Care. 2008 Feb;31 Suppl 2:S284-9. doi: 10.2337/dc08-s269. Diabetes Care. 2008. PMID: 18227498 Review.
The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.
Wynne K, Bloom SR. Wynne K, et al. Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):612-20. doi: 10.1038/ncpendmet0318. Nat Clin Pract Endocrinol Metab. 2006. PMID: 17082808 Review.
256 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page